Publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

 152
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

Next Article

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Examining the epigenetic transmission of risk for chronic pain associated with paternal post-traumatic stress disorder: a focus on veteran populations

Examining the epigenetic transmission of risk for chron...

 284

Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis

Serotonin transporter inhibits antitumor immunity throu...

 441

Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial

Cholesterol-lowering effects of oats induced by microbi...

 72